[go: up one dir, main page]

WO2019124863A1 - Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique - Google Patents

Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique Download PDF

Info

Publication number
WO2019124863A1
WO2019124863A1 PCT/KR2018/015747 KR2018015747W WO2019124863A1 WO 2019124863 A1 WO2019124863 A1 WO 2019124863A1 KR 2018015747 W KR2018015747 W KR 2018015747W WO 2019124863 A1 WO2019124863 A1 WO 2019124863A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
atopic dermatitis
active ingredient
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/015747
Other languages
English (en)
Korean (ko)
Inventor
김동선
이윤미
손은정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2019124863A1 publication Critical patent/WO2019124863A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • Atopic dermatitis is a type of hypersensitivity that has recently become increasingly prevalent as its prevalence increases rapidly. From the immunological point of view, the major symptoms caused by immunological reactions of immunoglobulin E and allergens It is defined as a group of allergic diseases with a strong genetic tendency.
  • atopic dermatitis a typical symptom of atopy, accounts for 0.5 to 1% of the total population and 5 to 10% of the children have serious symptoms, but it is presumed that they are related to genetic factors and immune system deficiency The exact cause has not been elucidated, and it is expected that it will be alleviated somewhat through the improvement of environment and diet, but there is no fundamental treatment method.
  • atopic dermatitis shows individual differences, most of them involve extreme itching, skin dryness, rashes, dirt, scabs, scaly skin (arthropods), and the resulting emotional anxiety, stress, Along with feelings of anger, other allergic diseases such as urticaria, metal allergies, asthma and allergic rhinitis, it is becoming a serious social problem that threatens the public health today.
  • representative drugs known to be effective for atopic dermatitis so far include steroids, antihistamines, antibiotics, non-steroids, and other sedatives and nerve stabilizers.
  • Schizandra chinensis is a dicotyledonous plant that is a magnolia plant of the Magnoliaceae. It grows mainly in valleys, the stem is brown and has the property of climbing trees. Leaves are alternate phyllotaxis, wide oval, long oval or ovate, with hairs on the back vein and tooth-like sawtooth on the edge. The flower is bloomed in June to July, is unisolated, and has a slightly reddish yellowish white color. After the flowering, the flower bud of the female flower grows to 3 ⁇ 5cm in length and the fruit runs on the water. Fruits are berries and they are almost round and have several spines.
  • Korean Patent Laid-Open Publication No. 2015-0027676 discloses a composition for preventing or treating metabolic syndrome-related diseases including an extract of Omija
  • Korean Patent Publication No. 2017-0017388 discloses a composition for preventing or treating metabolic syndrome
  • a composition for preventing or treating atopic dermatitis which comprises the extract of the present invention as an active ingredient has not been disclosed.
  • the present invention provides a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the present invention provides a composition for preventing, improving or treating atopic dermatitis, (TNF- ⁇ , IL-6) secretion in mast cells and secretion of chemokines (TARC, RANTES) in human keratinocytes (HaCaT cells)
  • TNF- ⁇ , IL-6 secretion in mast cells and secretion of chemokines (TARC, RANTES) in human keratinocytes (HaCaT cells)
  • the present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the present invention provides a cosmetic composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the present invention provides a quasi-drug composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the extract of Omija, an active ingredient of the present invention has antihistamine and NO production inhibitory effects on macrophages and mast cells It is.
  • the Omiza leaf extract has superior antihistaminic activity compared to the Omiza fruit or stem extract, and reduces secretion of cytokines (TNF- ⁇ , IL-6) from mast cells and suppresses the secretion of chemokines from human keratinocytes (HaCaT cells) TARC, and RANTES), the composition of the present invention can be usefully used as a composition for preventing, improving or treating atopic dermatitis.
  • FIG. 1 shows the results of analysis of the cell viability (%) of mummified cells of Omima leaf extract of the present invention and MC9 mouse treated with Omiza fruit extract and Omija stem extract of Comparative Example.
  • Fig. 2 shows the results of confirming the antihistamine effect in the mast cell treated with the extract of Omija leaf of the present invention and the comparative example of Omija fruit extract and Omija stem extract.
  • FIG. 3 shows the results of confirming the NO (%) scavenging activity in the mummified leaf extract of the present invention and the mast cell treated with the Schizosacraliana fruit extract of Comparative Example.
  • NMMA was a positive control and treated with 50 ⁇ M N-monomethyl arginine.
  • Fig. 4 is the cell viability (%) as determined by treating Omiza fruit extract and Omiza leaf extract with mast cells
  • FIG. 5 shows that secretion of cytokines (TNF- ⁇ , IL-6) in mast cells was increased.
  • TNF- ⁇ or IL-6 was increased statistically, p ⁇ 0.001.
  • *, **, *** indicate that the content of TNF- ⁇ or IL-6 decreased statistically compared to PMACI, *, p ⁇ 0.05, **, p ⁇ 0.01 Lt; 0.001.
  • $, And $ were significantly lower than those of Omiza fruit extracts at the same concentration.
  • the values of $, p ⁇ 0.05 and $$ were p ⁇ 0.01.
  • HaCaT cell human keratinocyte
  • FIG. 7 shows that the amount of chemokine (TARC, RANTES) secreted in human keratinocytes (HaCaT cell) was increased, and the amount of TARC or RANTES was increased statistically compared to control, # Is p ⁇ 0.01, and ### is p ⁇ 0.001.
  • *, ** and *** indicate that TARC or RANTES content decreased statistically compared to TI.
  • $$ and $$$ were statistically significantly lower than those of Omiza fruit extract in the same concentration. $$ is p ⁇ 0.01 and $$$ is p ⁇ 0.001.
  • the present invention relates to a pharmaceutical composition for preventing or treating atopic dermatitis, which comprises an extract of Omija leaf as an active ingredient.
  • the Omiza leaf extract may be produced by a method including, but not limited to, the following steps:
  • step 3 Concentrating the filtrate obtained in step 2) under reduced pressure and drying to prepare an extract.
  • the extraction solvent is preferably water, a C 1 -C 4 lower alcohol, or a mixture thereof, more preferably an ethanol extract, but is not limited thereto.
  • the vacuum concentration in step 3 may be performed using a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
  • composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned active ingredient, and may be various oral or parenteral formulations.
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
  • Solid formulations for oral administration include capsules, powders, granules, tablets, pills, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like.
  • Liquid formulations for oral administration include suspensions, emulsions, syrups, aerosols and the like.
  • excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin which are commonly used simple diluents.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • non-aqueous solvents and suspensions examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like.
  • examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
  • Intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, intraperitoneal, or intracerebral injection methods are preferably selected for parenteral administration, and most preferably used for external skin application.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the level of effective amount depends on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts.
  • the composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
  • the dosage of the composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease,
  • the dose is 0.01 to 2,000 mg / kg, preferably 30 to 500 mg / kg, more preferably 50 to 300 mg / kg, and can be administered 1 to 6 times a day.
  • the composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
  • the present invention also relates to a health functional food composition for preventing or ameliorating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the health functional food composition may be prepared by any one of powder, granule, ring, tablet, capsule, candy, syrup and beverage, but is not limited thereto.
  • the above-mentioned Omiza leaf extract may be directly added, used in combination with other food or food ingredients, and suitably used according to a conventional method.
  • the amount of active ingredient can be suitably determined according to its intended use (prevention, health or therapeutic treatment).
  • the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
  • the kind of the food There is no particular limitation on the kind of the food.
  • the foods to which the above extract can be added include meat products, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.
  • composition of the present invention When the composition of the present invention is used as a health drink, various flavors or natural carbohydrates may be added as an additional ingredient such as ordinary beverages.
  • natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as texturin and cyclotensitrin, and xylitol, sorbitol and erythritol.
  • sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention.
  • the composition of the present invention may further comprise various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid concentrating agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like.
  • the composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
  • the present invention also relates to a cosmetic composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • composition may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation and spray But is not limited thereto.
  • a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
  • the formulation of the cosmetic composition of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
  • the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.
  • the formulation of the cosmetic composition of the present invention is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • Propellants such as carbon, propane-butane or dimethyl ether.
  • the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative or ethoxylated glycerol fatty acid ester.
  • the cosmetic composition of the present invention may contain at least one ingredient capable of improving atopic dermatitis, which exhibits the same or similar functions in addition to the active ingredient.
  • the cosmetic composition of the present invention can be directly applied to skin using biodegradable micro needles or patches.
  • the present invention also relates to a quasi-drug composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.
  • the "quasi-drug composition” is a fiber, a rubber product or the like used for treating, alleviating, treating or preventing a disease of a human or an animal, Or products similar to those which are not machinery, preparations used for sterilization, insecticides and similar uses for the prevention of infections, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human beings or animals Means an article other than an apparatus, a machine or an apparatus, and an article other than an apparatus, a machine or an apparatus used for the purpose of giving a pharmacological effect to the structure and function of a person or an animal, But not limited to, personal hygiene products.
  • the quasi-drug composition of the present invention may be contained at various weight%, preferably 0.00001 to 10% by weight, as long as it can improve the effect of atopic dermatitis.
  • MC / 9 cells were diluted for each concentration for 24 hours, and cell viability was measured at 550 nm using a microplate reader (Molecular Devices, Sunnyvale, Calif., USA) using the MTT assay.
  • the cells were treated with PMA (50 nM) and A23189 (1 ⁇ M) in MC / 9 cells at appropriate concentrations in a 48-well plate and the Omiza leaf extract of the present invention and the Omiza fruit extract and Omija stem extract 50, 100 ⁇ ⁇ / ml) and cultured for 24 hours. After culturing the supernatant, the amount of histamine was measured according to the manufacturer's method using a histamine ELISA assay kit.
  • the Omiza leaf extract significantly decreased the amount of NO induced by LPS treatment.
  • Mouse mast cell MC / 9 cells were purchased from the American Type Culture Collection (ATCC, Rockville, Md., USA) and incubated with 10% heat-inactivated Fetal Bovine Serum (FBS), 100 units / ml penicillin, 100 and cultured in DMEM medium supplemented with streptomycin at 37 ⁇ ⁇ and 5% CO 2 .
  • FBS Fetal Bovine Serum
  • Cell Counting Kit-8 (CCK-8) assay was performed to determine the cytotoxicity of the extract. Samples were pre-treated for 30 minutes at concentrations of 25, 50, 100 and 200 ⁇ g / ml in MC / 9 mast cells in a 96-well plate and then treated with 20 nM PMA (phorbol myristate acetate) (calcium ionophore) A23187 was treated at a concentration of 0.5 ⁇ M and cultured. After 4 hours, CCK-8 was added to the medium at a concentration of 10%, and the mixture was reacted at 37 ° C. for 2 hours. Then, the absorbance at 450 nm was measured using a microplate spectrophotometer (Biorad, Hercules, CA, USA) , And relative cell viability (%) was calculated by comparison with the control group.
  • PMA phorbol myristate acetate
  • A23187 was treated at a concentration of 0.5 ⁇ M and cultured. After 4 hours, CCK-8 was added to the
  • the cultured MC / 9 mouse mast cells were inoculated in a 96-well plate and pretreated for 30 minutes at concentrations of 25, 50, 100 and 200 ⁇ g / ml. Then, PMA (phorbol myristate acetate ) And calcium ionophore A23187 were treated at a concentration of 0.5 ⁇ M and cultured for 4 hours. 0.1 and 1 ⁇ M of dexamethasone were each treated as a positive control. After 4 hours, secretion of cytokines (TNF- ⁇ , IL-6) secreted in the medium was measured by ELISA kit (R & D systems Inc., Minneapolis, MN, USA). 100% activity was calculated as the difference in the amount of cytokine secretion between the PMA and the A23187 untreated group.
  • amount of cytokine secretion (%) [(amount of cytokine secretion in the sample treated group - amount of cytokine secreted in the untreated group) / (amount of secreted cytokine in the control group - amount of cytokine secreted in the untreated group)] ⁇ 100.
  • Human keratinocyte HaCaT cells were cultured in DMEM medium supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), 100 units / ml penicillin and 100 ⁇ g / ml streptomycin at 37 ° C and 5 It was incubated at% CO 2 environment.
  • FBS Fetal Bovine Serum
  • Cell Counting Kit-8 (CCK-8) assay was performed to determine the cytotoxicity of the extract.
  • the cells were pretreated with HaCaT cells in a 96-well plate at concentrations of 25, 50, 100, 200 ⁇ g / ml and treated with 10 ng / ml of TNF- ⁇ and 10 ng / ml of IFN- , And cultured for 24 hours. After 24 hours, CCK-8 was added to the medium at a concentration of 10%, and the mixture was reacted at 37 ° C. for 2 hours. Then, the absorbance at 450 nm was measured using a microplate spectrophotometer (Biorad, Hercules, CA, USA) , And relative cell viability (%) was calculated by comparison with the control group.
  • the cultured keratinocyte human keratinocytes were inoculated on a 6-well plate and pretreated with the concentrations of 25, 50, 100, and 200 ⁇ g / ml. Then, 10 ng / ml of TNF- ⁇ and 10 ng / / Ml, and cultured for 24 hours. As a positive control, 0.1 and 1 ⁇ M of dexamethasone and 12 and 25 ⁇ g / ml of silymarin were treated, respectively. After 24 hours, secretion of chemokines (TARC, RANTES) secreted in the medium was measured by ELISA kit (R & D systems Inc., Minneapolis, MN, USA). 100% activity was calculated as the difference in the amount of chemokine secreted between the TNF-a and IFN-y (TI) treated groups.
  • TARC chemokines
  • amount of chemokine secretion (%) [(amount of chemokine secretion in the sample treated group - amount of chemokine in the untreated group) / (amount of secreted chemokine in the control group - amount of chemokine in the untreated group)] ⁇ 100.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition qui contient comme principe actif un extrait de feuilles de Schisandra chinensis et vise à prévenir, améliorer et traiter la dermatite atopique. L'extrait de Schisandra chinensis, le principe actif de la présente invention, a un effet antihistaminique sur les macrophages et les mastocytes, ainsi qu'un effet d'inhibition de la génération de NO. En particulier, l'extrait de feuilles de Schisandra chinensis présente une activité antihistaminique supérieure aux extraits de fruits et de tiges de Schisandra chinensis et induit une diminution de la quantité de cytokines (TNF-α, IL-6) sécrétées par des mastocytes tout en faisant également diminuer de manière significative la quantité de chimiokines (TARC, RANTES) dans les kératinocytes humains (cellules HaCaT), et, de ce fait, la composition de la présente invention peut être utilisée de manière fructueuse en tant que composition pour la prévention, l'amélioration et le traitement de la dermatite atopique.
PCT/KR2018/015747 2017-12-22 2018-12-12 Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique Ceased WO2019124863A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170177765A KR101874462B1 (ko) 2017-12-22 2017-12-22 오미자 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR10-2017-0177765 2017-12-22

Publications (1)

Publication Number Publication Date
WO2019124863A1 true WO2019124863A1 (fr) 2019-06-27

Family

ID=62920608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015747 Ceased WO2019124863A1 (fr) 2017-12-22 2018-12-12 Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique

Country Status (2)

Country Link
KR (1) KR101874462B1 (fr)
WO (1) WO2019124863A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101874462B1 (ko) * 2017-12-22 2018-07-05 한국 한의학 연구원 오미자 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR102107748B1 (ko) * 2019-08-30 2020-05-08 주식회사 아제라바이오텍 불로화, 오미자, 시호의 복합 추출물을 유효성분으로 포함하는 가려움증 완화 및 아토피 피부염의 예방 또는 치료용 조성물
KR102408103B1 (ko) 2020-05-20 2022-06-14 남종현 아토피 피부염 질환의 예방, 개선 또는 치료용 조성물
KR102576662B1 (ko) * 2021-10-15 2023-09-08 주식회사 하람 흑오미자 추출물을 유효성분으로 함유하는 환경호르몬에 의해 손상된 피부상태 개선용 조성물
KR102576659B1 (ko) * 2021-10-15 2023-09-08 주식회사 하람 흑오미자 추출물을 유효성분으로 함유하는 피부상태 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100483539B1 (ko) * 2002-12-10 2005-04-18 이진형 아토피성 피부염의 예방 또는 치료용 조성물 및 그 제조방법
KR100634289B1 (ko) * 2003-07-12 2006-10-16 오시환 아토피성 피부염 치료 보조제 및 그 제조방법
KR100717891B1 (ko) * 2004-11-25 2007-05-14 이지은 아토피성 피부염 관련 가려움증 완화 효과를 나타내는 화장료 조성물
KR101151567B1 (ko) * 2009-12-24 2012-07-10 사단법인 진안군친환경홍삼한방산업클러스터사업단 항알레르기 효능을 갖는 복합생약 추출물을 유효성분으로 함유하는 조성물
KR101874462B1 (ko) * 2017-12-22 2018-07-05 한국 한의학 연구원 오미자 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100483539B1 (ko) * 2002-12-10 2005-04-18 이진형 아토피성 피부염의 예방 또는 치료용 조성물 및 그 제조방법
KR100634289B1 (ko) * 2003-07-12 2006-10-16 오시환 아토피성 피부염 치료 보조제 및 그 제조방법
KR100717891B1 (ko) * 2004-11-25 2007-05-14 이지은 아토피성 피부염 관련 가려움증 완화 효과를 나타내는 화장료 조성물
KR101151567B1 (ko) * 2009-12-24 2012-07-10 사단법인 진안군친환경홍삼한방산업클러스터사업단 항알레르기 효능을 갖는 복합생약 추출물을 유효성분으로 함유하는 조성물
KR101874462B1 (ko) * 2017-12-22 2018-07-05 한국 한의학 연구원 오미자 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG, Y. H. ET AL.: "Inhibitory Effects of Schizandra Chinensis Extract on Atopic Dermatitis in NC/Nga Mice", IMMUNOPHARMACOL IMMUNOLOXICOL, vol. 34, no. 2, April 2012 (2012-04-01), pages 292 - 298 *

Also Published As

Publication number Publication date
KR101874462B1 (ko) 2018-07-05

Similar Documents

Publication Publication Date Title
WO2019124863A1 (fr) Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique
KR20190079202A (ko) 감귤류 열매를 이용한 유산균 발효 방법 및 이의 용도
KR20210128938A (ko) 병풀 발효 추출물을 유효성분으로 포함하는 염증, 주름, 알러지 및 아토피 피부염의 예방, 개선 또는 치료용 조성물
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
KR20150086982A (ko) 원지 추출물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물
WO2019132625A1 (fr) Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif
KR20210077426A (ko) 딸기 잎 및 줄기 혼합 추출물을 유효성분으로 포함하는 알러지성 질환의 예방, 개선 또는 치료용 조성물
WO2018186705A1 (fr) Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation
KR101077202B1 (ko) 감잎으로부터 추출된 헬리코박터 파이로리균에 대한 항균성추출물
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
KR20140043610A (ko) 모과나무 추출물을 유효성분으로 하는 과민성 면역질환 예방 또는 개선용 약학 조성물
KR102120758B1 (ko) 커피 추출물을 유효성분으로 포함하는 알러지성 질환의 예방, 개선 또는 치료용 조성물
WO2022124803A1 (fr) Composition destinée à la prévention, au soulagement ou au traitement de maladies allergiques, comprenant un extrait de spatholobus suberectus en tant que principe actif
WO2021235659A1 (fr) Composition pour la prévention, la réduction des symptômes ou le traitement de la dermatite atopique
KR102778316B1 (ko) 참비녀골풀 추출물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR102894756B1 (ko) 절패모 추출물을 유효성분으로 포함하는 면역증진 및 염증성 장질환의 예방, 개선 또는 치료용 조성물
KR101739425B1 (ko) 미나리 에탄올 추출물의 분획물을 유효성분으로 함유하는 염증성 질환 예방 또는 개선용 조성물
KR20200089527A (ko) 석창포 및 황칠 혼합 추출물을 포함하는 항염증용 조성물
WO2019103571A1 (fr) Composition destinée à traiter la dermatite, contenant un extrait et une fraction de parties aériennes de gypsophila oldhamiana miq et utilisation associée
KR102227261B1 (ko) 고욤 효소처리물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR102682338B1 (ko) 두충 추출물 및 진피 추출물을 포함하는 위장 장애의 예방, 개선 또는 치료용 조성물
WO2025023507A1 (fr) Composition pour la prévention, le soulagement ou le traitement de la dermatite atopique, contenant un extrait de scutellaria baicalensis et des graines de raphanus sativus l. en tant que principe actif
KR20230034591A (ko) 쇠고비 추출물을 포함하는 신경 퇴행성 질환 개선, 예방 또는 치료용 조성물
KR20250154615A (ko) 항염증용 조성물 및 이의 이용
WO2024219889A1 (fr) Composition contenant un mélange de tige et d'extrait de racine de chanvre en tant que principe actif pour effet apaisant la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890768

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18890768

Country of ref document: EP

Kind code of ref document: A1